TY - JOUR
T1 - An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination
AU - Wang, Yongchao
AU - Gong, Ningqiang
AU - Ma, Chi
AU - Zhang, Yuxuan
AU - Tan, Hong
AU - Qing, Guangchao
AU - Zhang, Jimei
AU - Wang, Yufei
AU - Wang, Jinjin
AU - Chen, Shizhu
AU - Li, Xianlei
AU - Ni, Qiankun
AU - Yuan, Yuan
AU - Gan, Yaling
AU - Chen, Junge
AU - Li, Fangzhou
AU - Zhang, Jinchao
AU - Ou, Caiwen
AU - Zhao, Yongxiang
AU - Liu, Xiaoxuan
AU - Liang, Xing Jie
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Immunological adjuvants are essential for successful cancer vaccination. However, traditional adjuvants have some limitations, such as lack of controllability and induction of systemic toxicity, which restrict their broad application. Here, we present a light-activable immunological adjuvant (LIA), which is composed of a hypoxia-responsive amphiphilic dendrimer nanoparticle loaded with chlorin e6. Under irradiation with near-infrared light, the LIA not only induces tumour cell lysis and tumour antigen release, but also promotes the structural transformation of 2-nitroimidazole containing dendrimer to 2-aminoimidazole containing dendrimer which can activate dendritic cells via the Toll-like receptor 7-mediated signaling pathway. The LIA efficiently inhibits both primary and abscopal tumour growth and induces strong antigen-specific immune memory effect to prevent tumour metastasis and recurrence in vivo. Furthermore, LIA localizes the immunological adjuvant effect at the tumour site. We demonstrate this light-activable immunological adjuvant offers a safe and potent platform for in situ cancer vaccination.
AB - Immunological adjuvants are essential for successful cancer vaccination. However, traditional adjuvants have some limitations, such as lack of controllability and induction of systemic toxicity, which restrict their broad application. Here, we present a light-activable immunological adjuvant (LIA), which is composed of a hypoxia-responsive amphiphilic dendrimer nanoparticle loaded with chlorin e6. Under irradiation with near-infrared light, the LIA not only induces tumour cell lysis and tumour antigen release, but also promotes the structural transformation of 2-nitroimidazole containing dendrimer to 2-aminoimidazole containing dendrimer which can activate dendritic cells via the Toll-like receptor 7-mediated signaling pathway. The LIA efficiently inhibits both primary and abscopal tumour growth and induces strong antigen-specific immune memory effect to prevent tumour metastasis and recurrence in vivo. Furthermore, LIA localizes the immunological adjuvant effect at the tumour site. We demonstrate this light-activable immunological adjuvant offers a safe and potent platform for in situ cancer vaccination.
UR - https://www.scopus.com/pages/publications/85112718917
U2 - 10.1038/s41467-021-25197-z
DO - 10.1038/s41467-021-25197-z
M3 - 文章
C2 - 34400628
AN - SCOPUS:85112718917
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4964
ER -
可持续发展目标 3 良好健康与福祉